PLI-MD closes to new applicants in March 2027 — the scheme is done taking entrants. Checked against the FY2025-26 trade data, it has genuinely moved the needle in imaging and implants, but never touched the two largest deficit families: lab instruments and IVD reagents. This maps exactly what's addressed, what's covered on paper but not in practice, and where the live SMDI/PRIP windows should go next.
PLI for Medical Devices: What's Covered, What Isn't — and Where to Apply Next
0. The rule that frames everything
Per the Department of Pharmaceuticals' own statement to Lok Sabha (16 December 2025): since the scheme closes in March 2027 with a one-year gestation period, no further rounds of application are under consideration. “Newly apply” therefore cannot mean a new PLI-MD application. The open doors are the SMDI (Scheme for Strengthening of Medical Device Industry) components window, live since June 2026; PRIP (Promotion of Research and Innovation in Pharma-MedTech), for novel-device and IVD R&D; the four Medical Device Parks (Himachal Pradesh, Madhya Pradesh, Tamil Nadu, Uttar Pradesh); and the evidence base for a future PLI 2.0.
1. What PLI already addresses · 28 approved projects, ₹1,094cr invested, ₹5,753cr cumulative exports to Sep 2025
| Target segment | Devices under manufacture | Trade-data verdict, FY2025-26 |
|---|---|---|
| 1. Cancer care / radiotherapy | LINAC, rotational cobalt, laser ablation (Panacea, Meril Innovations) | Early stage: radiotherapy imports (within the 9022 family) still growing; Panacea exports ₹36cr. |
| 2. Radiology & imaging | CT, MRI, MRI coils, mammography, X-ray, C-arm, cath lab, PET detector, flat-panel detectors (Siemens, Wipro GE, Allengers, BPL, Trivitron, Philips, GE BE, Varex) | Visibly working: MRI imports fell 8.5% to $298mn; Philips MRI-coils alone: ₹2,187cr cumulative exports, the scheme's biggest exporter. But family imports still +27% — demand outruns capacity. |
| 2b. Imaging components (Cat-B) | X-ray tube housings, anode/cathode assemblies (Motherson), flat-panel detectors (Varex) | Right idea, one applicant deep. X-ray tube imports still +165% to $231mn — needs many more entrants. |
| 3. Anaesthesia, cardio-respiratory & renal | Anaesthesia workstations, ventilators, oxygen concentrators, ECG, patient monitors, defibrillators, dialyser, dialysis machine, HD catheter (Allied, BPL, Nipro, Poly Medicure, Omron, Wipro GE) | Renal is the success: Nipro ₹902cr exports, dialysis coverage 71%. Oxygen/respiratory is not: imports +30% with 9% coverage despite four concentrator makers. |
| 4. Implants incl. implantable electronics | Hip/knee/trauma implants, heart valves, stents, PTCA balloons, hernia mesh, neurovascular devices (Meril ×4, SMT, Envision, Innvolution, Neurovasive, Majik) | Strong: Meril group ₹2,200cr exports; joints coverage 44–69% and rising. |
| 3b/4b. Urology (Cat-B) | Full catheter/stent/guidewire/lithotripsy-laser range (Indovasive) | Niche but real; catheters already a national strength. |
Source: DoP approved-applicant list (revised 25 Apr 2023); PIB 16 Dec 2025 (progress annexures); trade verdicts from the FY2025-26 TradeStat fetch in the companion post.
PLI has genuinely started fixing equipment — imaging, monitoring, renal, implants. Its measurable wins (MRI import decline, coils/dialyser/stent exports) are exactly where applicants invested. Its weak spots: capacity far below demand (imaging imports still +27%), single-applicant component lines, and two segments on the official 38-device list with little production behind them yet.
2. Covered on paper, not in practice
- Pacemakers — inside Segment 4's scope (“implantable electronic devices”), yet no applicant makes one: imports $64mn at 1% export coverage, every implanted unit imported.
- Ultrasound probes/transducers — the machines are covered (three applicants); the probe, the value core, is not separately localised.
- X-ray tubes/generators at scale — one housing maker (Motherson) and one detector maker (Varex) against a $231mn, +165% import line.
- Oxygen concentrators — four applicants, near-zero exports, imports still +30%: a procurement/demand-side problem, not a capacity problem.
3. Not addressed by PLI at all — the newly-apply list · ranked by FY2025-26 import gap
- Lab & analytical instruments (HS 9027) — $2.19bn imports, 10% coverage, zero PLI presence: chromatographs ($335mn, 3% coverage), gas analysers ($298mn, coverage % not available in the TradeStat fetch), mass spectrometers ($116mn, 1% coverage). The largest single unaddressed family; every CDSCO/pharma QC lab is captive demand.
- IVD reagents, kits & analysers (HS 3822) — ~$1.1bn, 9–31% coverage, no PLI applicant despite Segment 4 nominally “including IVD”. Immunoassay/molecular reagents and closed-system analysers are the gap. Natural PRIP + SMDI candidates.
- Contrast media & X-ray film — $77mn (60% China) and $108mn (2% coverage, 35% Japan) respectively; chemistry-adjacent, no scheme presence.
- Ophthalmic surgical instruments — $252mn, +24%, 18% coverage. World's largest cataract-surgery base plus the Aurolab IOL precedent, yet no ophthalmic line in PLI.
- Endoscopes (rigid/flexible medical) — $112mn imports, 57% coverage, Japan-dominated; only a urology-niche Cat-B applicant covers this space.
- Dental ecosystem — instruments/drills ($112mn, 34% China), chairs, cements: nothing in PLI.
- Hearing aids — meaningful import value, zero applicants despite Segment 4 scope; high-volume, electronics-assembly friendly.
- Surgical instruments residual ($822mn combined, 17–22% coverage) — the biggest single HS line in the basket; an MSME cluster play (park + common-facility economics), not large-cap PLI.
- Medical furniture (HS 9402) — $69mn, +14%, 28% coverage; hospital beds/OT tables, low-tech, park-ready.
- Component layer across all machines — the ~$1.7bn parts & accessories residuals: precisely what SMDI's import-dependency sub-scheme exists for; Motherson/Varex prove the model.
4. Bottom line
PLI-MD, now closed to new applicants, addressed capital-equipment finals and implants — imaging, anaesthesia/ventilation, renal care, monitoring, cardiac and orthopaedic implants — and the trade data confirms real movement exactly there. It never touched the two biggest deficit families (lab/analytical instruments, IVD reagents) and left pacemakers, ophthalmic instruments, endoscopes, dental, hearing aids and the components layer open. Those are the lines for the SMDI window opened June 2026, PRIP, the four device parks, and the evidence file for any PLI 2.0. One of those gaps is not what it looks like: endoscopes already run 57% export coverage, ahead of most categories PLI actually subsidised — see the piece on that anomaly. See the trade-scenario piece for the full family-by-family import/export picture this builds on.
Sources. Department of Pharmaceuticals PLI-MD scheme page; approved-applicant list, revised 25 April 2023 (Category A + B); PIB 16 December 2025 (Press Release ID PRID 2204598 — progress annexures: 28 projects, investment to Sep 2025, cumulative exports & employment); PIB 13 February 2026 (Press Release ID PRID 2227618 — official list of 38 high-end devices manufactured under PLI); trade verdicts from the FY2025-26 (provisional) TradeStat fetch of 5 August 2026 described in the companion post.
About this article: Researched, written and edited by Umashankar Triplicane Dwarakanathan, with AI research assistance; every figure is meant to trace to the primary source cited. See the Editorial Policy for how sourcing, AI use and corrections work.
